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Carbonylation as a novel method for the assembly
of pyrazine based oligoamide alpha-helix
mimetics†
Seger Van Mileghem,‡a Brecht Egle,‡a Philippe Gilles,a Cedrick Veryser,a
Luc Van Meerveltb and Wim M. De Borggraeve*a
The design and synthesis of oligoamide α-helix peptidomimetics is reported. The oligoamide type
systems are prepared in a modular fashion by coupling the monomers using palladium-catalyzed
carbonylation chemistry. This enabled us to use substrates with a low nucleophilicity, leading to previously
unreported pyrazine based oligoamide α-helix mimetics. The proof of principle is given by synthesizing a
small set of compounds. Various end-capping groups were introduced and also a mixed multimer was
successfully prepared.
Introduction
Protein–protein interactions (PPI), because of their importance
in biological processes, are interesting though diﬃcult targets
for potential therapeutic applications. With good reason PPI
were once considered undruggable, mostly because of their
large (1500–3000 Å2) and shallow but dynamic interaction
surfaces.1 Fortunately, in most cases, the interaction is highly
dependent on just a small number of key amino acid residues.
These are located on the interaction surface, forming a so
called hot spot.2 Currently, the number of small molecule
protein–protein interaction inhibitors is increasing.1,3–5
Analysis of multiprotein complexes in the Protein Data Bank
by the Arora group has shown that in more than 60% of the
cases, α-helices are present in the interaction surfaces.6 Hence,
mimetics of this secondary structure element show significant
medicinal potential. Due to the nature of PPIs, small mole-
cules targeting these interactions can lie beyond Lipinski’s
rule of five.7 Several approaches exist where the helical back-
bone is replaced by a small molecule core decorated with
amino acid side chains in the same spatial positions as in an
α-helix at relative positions i, i + 3/i + 4, i + 7 of the α-helix. A
multitude of such minimalist peptidomimetics8–18 have been
reported in the last two decades. A remarkable class of mole-
cules are the oligoamide systems which have shown potency in
the modulation of protein–protein interactions.19
Central in the design of these oligoamide systems is the
modularity in synthesis. This elegant concept provides an
unambiguous strategy for the assembly of monomeric units to
multimers. Among the oligoamide type systems described in
the literature (some examples in ref. 20–23 and Scheme 1A),
amide bond formation is not always straightforward.24 The
amide synthesis is typically performed via acyl chlorides or
via the corresponding carboxylic acid with specialty coupling
reagents (e.g. Ph3PCl2,
25 Ghosez’s reagent26 and Mukaiyama
reagent27) since the amine coupling partners are not always
nucleophilic. Due to the elaborate synthetic work, significant
eﬀorts have been made towards solid phase synthesis and
recently, late stage introduction of the amino acid residues.26,28
Here, we report on palladium-catalyzed carbonylation as
an alternative strategy for the assembly of monomers
(Scheme 1B). The use of catalytic carbonylation chemistry as a
coupling method is advantageous since (1) no stoichiometric
amounts of coupling reagents are used, (2) it oﬀers a broad
functional group tolerance and (3) it is able to handle sub-
strates which are very low in nucleophilicity.29
Previous experience with peptidomimetics30 and carbonyl-
ation31 in our group motivated us to combine this knowledge to
pursue the synthesis of unreported pyrazine based oligoamide
α-helix peptidomimetics via palladium-catalyzed carbonylation.
This scaﬀold has the interesting feature of increasing hydro-
philicity and solubility by adding hydrogen bond acceptors that
can contribute to a so called wet edge.32,33 The modularity in
design by using carbonylation chemistry enabled us to synthesize
both pyrazine based multimers as well as a hybrid dimer.
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Results and discussion
Retrosynthesis
It was proposed that the pyrazine based multimeric structure
(Scheme 2) mimics the amino acid residues at the same face of
the helix as its phenyl and pyridine counterparts,34 namely at
the i, i + 4 and i + 7 positions. Building block 1 (or its pro-
tected version 2) consists of a pyrazine core which enabled the
development of a modular route (Scheme 2). The idea is
inspired by peptide synthesis where a sequence of activation,
coupling and deprotection is repeated a number of times to
synthesize (oligo)peptides. Similarly, in our strategy, building
blocks 2 serve as a substrate for the growing oligoamide multi-
mers via a palladium-catalyzed carbonylation with CO gas,35
which are then deprotected to prepare them for the next coup-
ling. The main reason for using aminocarbonylation as the
coupling methodology is due to its ability to couple substrates
which are low in nucleophilicity, such as aminopyrazine
derivatives.36 Moreover, the reaction conditions of carbonyla-
tion chemistry are mild and therefore compatible with sensi-
tive amino acid side chains present on the peptidomimetics.35
We recently reported a carbon monoxide precursor system
based on the elegant two-chamber setup of the Skrydstrup
group.31,37 In order to avoid the use of a CO lecture bottle and
CO filled balloons, this setup was successfully used in a later
stage for carbonylation couplings for the sake of safety (see the
ESI†).
In order to avoid homocoupling and polymerization, the
first building block needs to have its halide group replaced
with a moiety that cannot interfere in the following palladium-
catalyzed coupling. This is a so called end-capping group,
which in the peptide synthesis analogy corresponds to block-
ing the C-terminal amino acid by formation of e.g. an ester or
attachment to a solid support. The end-capping can be done
via carbonylation chemistry or other cross-coupling chemistry,
such as Suzuki coupling38 forming biaryl type compounds (Y =
Ar). Deprotection of an end-capped scaﬀold yields 4 that is
ready to be coupled with another Boc-protected building
block (2) via carbonylation. Finally, another iteration of the de-
protection/coupling followed by a final deprotection yields the
pyrazine based α-helix peptidomimetic trimer (8). To demon-
strate this proof of principle, a range of monomeric building
blocks was synthesized which were assembled into a set of
multimers.
The Boc-protected aminopyrazines (2, Scheme 2) allow easy
preparation of mixed multimers, containing both pyrazine and
other types of monomers (e.g. phenyl scaﬀolds). This not only
increases the potential structural diversity but also allows
tuning the conformational rigidity of the multimers, which
has been demonstrated to be advantageous for some PPI
targets.39
Synthesis
In a first stage the synthesis of pyrazine building blocks is per-
formed (Table 1). Aminopyrazine is dibrominated using NBS
in DMSO.40 Following bromination, the desired amino acid
mimicking side chain41 was attached using a fully regio-
selective SNAr in THF.
40,42 Table 1 summarizes the scope of the
synthesized pyrazine building blocks. Monomers 1a–d were
prepared in excellent yields. Following the synthesis of the
monomers, we embarked upon the assembly of multimers.
Some examples are depicted in Scheme 3. After Boc-protection
Scheme 1 (A) An α-helix next to known oligoamide type helix mimetics.
(B) Our proposed strategy towards pyrazine based peptidomimetics.
Scheme 2 Retrosynthetic approach to pyrazine based trimers.
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of 1, an alkoxycarbonylation was performed to synthesize
methyl ester end-capped building blocks 3 in good yields.
Subsequently, the Boc groups were removed under acidic con-
ditions. In a following step dimers 5a and 5b were synthesized
and subsequently deprotected. The last two steps were
repeated to obtain trimers 8a and 8b.
X-ray analysis of 6b confirms the presence of intramolecular
hydrogen bonds, in analogy to the oligoamide pyridine
counterparts.34 An overlay image of our dimer 6b with a benz-
amide43 and pyridine analog44 is shown in Fig. 1 (see the ESI†
for the refined structure with the according thermal
ellipsoids). It was observed that the distance between the
O-alkylated side chains is slightly smaller than is observed for
the benzamide system (Fig. 1). This is a result of the additional
hydrogen bond between the amide proton and pyrazine nitro-
gen, as was also the case for the pyridine dimer.44 The pres-
ence of this hydrogen bond is also responsible for the stronger
downfield shift of the amide proton in comparison with the
one in our hybrid system (10.09 ppm for 10 vs. 8.45 ppm for
14) and the benzamide and pyridinyl amide systems described
in the literature.34,44 Furthermore, a smaller angle of incli-
nation is observed (155.9° versus 159.6° for our pyrazine
system and the reported benzamide system, respectively). This
Table 1 Synthesis of the pyrazine building blocksa
Entry Base Product Yield (%) AA residue
1ab NaH 83 Ala
1b NaHMDS 88 Leu
1c NaH 81 Phe
1dc NaH 91 Val
a Conditions: 0.2 M pyrazine in THF, 1.5 eq. alcohol, 1.5 eq. base,
50 °C, overnight. b 1.1 eq. NaOMe in MeOH. c 10 eq. iPrOH and 3 eq.
NaH.
Scheme 3 Synthesis of pyrazine based methyl ester end-capped α-helix peptidomimetics. Reagents and conditions: (a) Boc2O, DMAP, DCM, reﬂux.
(b) MeOH, Pd(OAc)2, xantphos, CO, Et3N, 80 °C. (c) TFA, DCM or H2O, reﬂux. (d) 2a or 2b, Pd(OAc)2, xantphos, CO, Na2CO3, toluene, 100 °C. (e) TFA,
DCM or H2O, reﬂux. (f ) 2a, 2b or 2c, Pd(OAc)2, xantphos, CO, Na2CO3, toluene, 100 °C. (g) TFA, DCM.
Fig. 1 Overlay analysis of Wilson’s benzamide crystal (CCDC 870274),
Hamilton’s pyridine crystal (CCDC 697087) and our pyrazine crystal
(CCDC 1512413).
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clearly shows the structural resemblance between our and
known systems. However, a more exact evaluation of which
residues in a helix can be mimicked by these scaﬀolds would
require a more detailed analysis (EKOS).45
In the case of dimer formation, an amount up to 30% of
Buchwald–Hartwig amination46 side product was observed. This
was confirmed by X-ray crystallography (see the ESI†). For the
synthesis of 5b, the amination product (5b′, not shown) was iso-
lated in 29% yield. These findings correlate with a report of
Buchwald et al.,47 describing that in a palladium/xantphos
system the preferred reaction conditions are electron deficient
aryl halides combined with electron deficient nucleophiles,
which is the case for our pyrazine substrates. On the other
hand, the low trimer formation yields might be due to the poor
solubility of the dimers in toluene, since significant amounts of
the starting materials were recovered. Other solvents commonly
used in carbonylation chemistry (such as dioxane, THF and
DMF) did not improve the yield of these reactions.
In a next example, Suzuki cross coupling was used as
end-capping chemistry. This is demonstrated in Scheme 4.
Building block 1a was end-capped to obtain compound 9. Boc-
protected building block 2c was attached via carbonylation,
which after deprotection led to dimer 10. Alternatively, other
aryl building blocks can also be introduced as the second
monomeric unit via this modular synthesis. This is demon-
strated in Scheme 5. Phenyl monomer 13 was synthesized
starting from p-nitrobromobenzene (11) via a vicarious nucleo-
philic substitution which was carried out in a mixture of THF
and liquid ammonia.48 The resulting phenol 12 was treated
with p-fluorobenzyl alcohol in a Mitsunobu reaction to yield
13.49 Finally, this monomer was coupled with 9, which gave
rise to hybrid dimer 14.
Similar to the reported oligoamide systems, the water solu-
bility of our multimers remains problematic. However, the
introduction of a water solubilizing end capping group is poss-
ible via the carbonylation strategy. When end-capping 2d with
N-methylpiperazine (not shown), only traces of the desired
product were obtained. As it appears, secondary amines react
with anilinic carbamate groups, forming unsymmetrical ureas
at elevated temperatures and deprotecting the pyrazine.50
Fortunately, when performing this carbonylation with un-
protected monomer 1d, the end-capped product 15a was
obtained (Scheme 6). A similar result was achieved when using
monomer 1a. Compound 15a was then coupled with 2b. After
deprotection this gave 16, which mimics an α-helix with valine
and leucine residues. The water solubility problem was
however not solved by introducing the piperazine moiety.
Conclusion
In conclusion, a modular synthesis protocol has been devel-
oped towards previously unreported oligoamide pyrazine based
α-helix peptidomimetics, as well as a hybrid type derivative. A
coupling–deprotection sequence was used, utilizing a palla-
dium-catalyzed aminocarbonylation to form the amide bonds
between poorly nucleophilic aminopyrazine type building
blocks. This methodology enables the flexible synthesis of a
diverse set of (hetero)aryl oligoamide α-helix peptidomimetics.
The synthesis also features the introduction of various end
capping groups via (carbonylative) cross coupling reactions.
Attempts to improve trimer formation yields are currently in
progress.
Scheme 5 Synthesis of a hybrid dimer containing both a phenyl and
pyrazine moiety. Reagents and conditions: (a) cumene hydroperoxide,
NH3 : THF, −33 °C, 57%. (b) p-Fluorobenzyl alcohol, PPh3, DIAD, THF,
62%. (c) 9, Pd(OAc)2, xantphos, CO, Na2CO3, toluene, 100 °C, 65%.
Scheme 6 Synthesis of dimer HCl salt by piperazine end-cap. Reagents
and conditions: (a) N-methylpiperazine, Pd(OAc)2, xantphos, CO, Na2CO3,
toluene, 100 °C. (b) 1. 2b, Pd(OAc)2, xantphos, CO, Na2CO3, toluene,
100 °C, 17% (43% with recovery of 15a). 2. TFA, DCM, 97%. 3. HCl,
dioxane, quant.
Scheme 4 Synthesis of pyrazine based Suzuki end-capped α-helix
peptidomimetics. Reagents and conditions: (a) (3-methoxyphenyl)
boronic acid, Pd(OAc)2, K2CO3, S-Phos, ACN : H2O, 100 °C, 73%. (b) 1. 2c,
Pd(OAc)2, xantphos, CO, Na2CO3, toluene, 100 °C, 21%. 2. TFA, DCM,
Quant.
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